Streetbeat News

Stock Prices

UNH

UnitedHealth Group (NYSE:UNH) has received 19 analyst ratings in the last quarter, all of which are bullish or somewhat bullish. The average price target is $589.74, representing an upside from the current price of $463.05. This average is a 2.22% decrease from the previous average price target of $603.11.

Portfolio Pulse from Benzinga Insights

July 11, 2023 | 1:00 pm

PAYO

Analysts have given Payoneer Global (NASDAQ:PAYO) mostly bullish ratings in the last quarter, with an average price target of $8.5, indicating potential upside from the current price of $4.83. However, this average has decreased by 15.0% from the previous average price target of $10.00.

Portfolio Pulse from Benzinga Insights

July 11, 2023 | 1:00 pm

SPY

The USA Redbook Year-over-Year (YoY) has reported a decrease of 0.4%, compared to the previous 0.7%.

Portfolio Pulse from Happy Mohamed

July 11, 2023 | 12:56 pm

CSE:CHV

Canada House Cannabis Group Inc. (CSE:CHV) and Montréal Cannabis Médical Inc. (MTL Cannabis) have entered into a second restated share exchange agreement. This agreement is for the completion of the second tranche of Canada House's acquisition of all issued and outstanding shares of MTL Cannabis. The transaction constitutes a 'reverse takeover' of the company, and upon completion, the company will change its legal name to MTL Cannabis Corp., with its common shares to trade on the CSE under the ticker symbol 'MTLC'.

Portfolio Pulse from Vuk Zdinjak

July 11, 2023 | 12:54 pm

USO

The Saudi Cabinet has reaffirmed its commitment to bolster OPEC+ precautionary measures to stabilize oil markets, according to Reuters. This could potentially impact the United States Oil Fund (USO).

Portfolio Pulse from Benzinga Newsdesk

July 11, 2023 | 12:50 pm

NIO

NIO Inc's stock has been on the rise, with shares trading higher after an 8% increase on Monday. The stock is now up more than 20% over the last month. This is due to Nio's delivery update for the second quarter and June, where it reported delivering 10,707 vehicles in June, up from 6,155 vehicles in May. The company also launched and commenced deliveries of the ET5 Touring in mid-June and started ramping up deliveries of its ES8 SUV toward the end of the month.

Portfolio Pulse from Adam Eckert

July 11, 2023 | 12:48 pm

OWLT

Owlet, Inc. (NYSE:OWLT) has announced that the New York Stock Exchange (NYSE) has accepted its business plan to regain compliance with the continued listing standards. The company was previously not in compliance due to its average global market capitalization and stockholders' equity being less than $50 million. The NYSE has given Owlet an 18-month cure period to regain conformity. A 1-for-14 reverse stock split of the Common Stock became effective on July 7, 2023, which the company expects will help it regain compliance with the $1.00 minimum average closing price requirement of the NYSE.

Portfolio Pulse from Happy Mohamed

July 11, 2023 | 12:47 pm

ADCT

ADC Therapeutics SA has voluntarily paused enrollment of new patients in the Phase 2 LOTIS-9 trial evaluating Zynlonta and rituximab in patients with untreated diffuse large B-cell lymphoma. This decision comes after a review of data from the 40 patients enrolled in the trial, which indicated potentially excessive respiratory-related events. The company does not expect to report additional data from the trial by the end of the year. ADCT shares are down 15.60% at $2.00 during the premarket session.

Portfolio Pulse from Vandana Singh

July 11, 2023 | 12:47 pm

AMH

AVB

CPRT

CVNA

EQR

ESS

INVH

KMX

LAD

Goldman Sachs predicts a larger-than-expected drop in core inflation for June and a continued downward trend in the consumer price index (CPI) inflation. The firm forecasts a decrease in used car prices, a decline in travel-related categories due to negative residual seasonality, and a moderate slowdown in shelter inflation. Companies operating in the used car market and house rental market may be impacted.

Portfolio Pulse from Piero Cingari

July 11, 2023 | 12:46 pm

ADCT

ADC Therapeutics has paused enrollment in its Phase 2 LOTIS-9 trial of Zynlonta and rituximab in unfit or frail patients with previously untreated diffuse large b-cell lymphoma. This has led to a decrease in the company's share price.

Portfolio Pulse from Benzinga Newsdesk

July 11, 2023 | 12:46 pm